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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S392characterized by pain and/ or stiffness of knee and/ or hip. They were
included at the ﬁrst visit or within 6 months of the ﬁrst visit to the
general practitioner for these symptoms. Study centers comprise ten
general and university hospitals located in urbanized and semi-
urbanized regions in the Netherlands. A special programwas developed
to minimize loss to follow up, comprising newsletters, website and
organizing symposia to present the results and progress of CHECK. An
overview of measures that are included in the study can be found at our
website www.check-research.com.
Results: After 7 years a total of 105 (10%) participants had dropped out.
Reasons included loss of interest (21%), comorbidity that complicated
participating of CHECK too much (18%), death (12%), contact lost (11%),
costs incurred for the study (5%), and other reasons (33%). Dropouts did
not differ signiﬁcantly from other participants in baseline character-
istics. Over 7 years follow-up clinical characteristics including pain,
stiffness and function of disease-speciﬁc (WOMAC) and the subscales of
generic self-report questionnaire (SF36) on average did not change
signiﬁcantly, although at least half of the patients experienced radio-
graphic progression. Scoring of 5-year follow up is complete: at this
point, 50 % of the participants progressed by at least one Kellgren and
Lawrence grade in the knee, and 25% in the hip. Preliminary analyses
suggest the existence of several clinical and radiological phenotypes.
Conclusions: CHECK is a valuable source of information of early
symptomatic OA with a low loss to follow-up and a multidisciplinary
approach that allows the collections of high-quality data on clinical,
radiological and biochemical variables.
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CALCIUM CRYSTALS DETECTED BY SCANNING ELECTRONIC
MICROSCOPY IN SYNOVIAL FLUID OF PATIENTS WITH EARLY KNEE
OSTEOARTHRITIS. RELATIONSHIPS WITH INFIAMMATION AND
DISEASE SEVERITY
R. Ramonda y, P. Frallonardo y, L. Peruzzo z, L. Tauro x, A. Scanu y,
M. Lorenzin y, A. Ortolan y, P. Galozzi y, F. Oliviero y, L. Punzi y.
yRheumatology Unit, Univ. of Padova, Padova, Italy; z Inst. for GeoSci.s
and Earth Resources IGG-CNR, Padova, Italy; xDept. of GeoSci.s, Univ. of
Padova, Padova, Italy
Purpose: The presence of calcium crystals (CC) in synovial ﬂuid (SF) of
osteoarthritis (OA) is a well known and frequent feature. However, their
role in the pathogenesis of OA is still unclear andmatter of discussion, in
particular as regard the local inﬂammation. The objective of the study
was to evaluate the presence of the most common CC, calcium pyro-
phosphate (dehydrate) (CPP) and basic calcium phosphate (BCP), in SF
of the symptomatic knee OA (KOA, particularly in early disease stage
(<1year) and to investigate their association with local inﬁammation,
disease activityand severity. We performed an ultrasensitive analysis of
SF crystals using the scanning electron microscopy (SEM) and the
routinary method by compensated polarized ligth microscopy (CPLM)
and alizarin red staining.
Methods: Seventy-four (48 F, mean age 64.859.33 yrs, range 50-89
yrs) consecutive outpatients attending theRheumatology Unit, Uni-
versity of Padova with symptomatic KOA (according to the American
College of Rheumatology criteria) underwent knee arthrocentesis. After
optical and CPLM, the SF was analysed by SEM. Total white blood cell
(WBC) count was performed and a cut-off of total WBC was establishedDSPCC 35 m
SF-36 Physical Component Score (n [ 94)
Mean change from baseline to week 12 7.58*
SF-36 Domain Scores (n[ 94)
Physical functioning score mean change from baseline to week 12 5.99*
Role physical score mean change from baseline to week 12 7.71*
Bodily pain score mean change from baseline to week 12 8.87*
General health score mean change from baseline to week 12 2.19
Vitality score mean change from baseline to week 12 4.86*
Social functioning score mean change from baseline to week 12 5.65*
Role emotional score mean change from baseline to week 12 3.87
Mental health score mean change from baseline to week 12 1.77
DSPCC, diclofenac submicron particle containing capsules; TID, three times daily; BID, tw
*P  0.03. Bold values represent scores  minimally clinically important difference (2.
Data above presented as means however, all P-values are compared with placebo and cin < 1000/mm3. Patients’ medical history, clinical features (WOMAC,
Lequense and VAS) X-ray ﬁndings (Kellgren & Lawrence), ultrasound
and power Doppler (PD) signal values were also assessed.
Results: CPP crystals were identiﬁed in 32.4% by CPLM and in 31.1% by
SEM. Alizarin was positive in 36.5% of the samples. BCP were found in
13.5% by SEM. CPP and BCP crystals were simultaneously positive in
8.1% of the samples by SEM. The study population was divided into
three groups depending on disease duration (group A <1 yr; group B 1-
5 yrs; group C > 5 yrs). The SF volume (p¼0.0008) was signiﬁcantly
different in the group Awith respect to B and C groups. The SFWBC was
higher during the early stages of disease (group A), although not sig-
niﬁcant, with respect to B and C groups. Moreover, the presence of CC in
group A correlated signiﬁcantly with SF WBC (p¼0.048) and % of PMN
(p¼0.033) with respect to those without CC in the same group. PD
resulted positive in 43.24% of all the patients, 62.5% of these were CCþ
according to SEM (p<0.0001).
Conclusions: The presence of CC in SF, also when detected in early OA
stages, was associated with a higher degree of local inﬂammation, so
suggesting that they may play a role of in eliciting an inﬂammatory
reaction, which may be crucial in OA pathogenesis.
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A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF LOWER-DOSE
DICLOFENAC CAPSULES IN PATIENTS WITH OSTEOARTHRITIS PAIN:
IMPACT ON PATIENT-REPORTED OUTCOMES
V. Strand y, M. Bergman z, D. Parenti x, J. Nezzer k, C. Young x. y Stanford
Univ., Palo Alto, CA, USA; zDrexel Univ. Coll. of Med., Philadelphia, PA, USA;
x Iroko Pharmaceuticals, LLC, Philadelphia, PA, USA; k Premier Res.,
Philadelphia, PA, USA
Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are fre-
quently prescribed for management of osteoarthritis (OA) pain and
diclofenac is the most frequently used prescription and over-the-
counter NSAID worldwide. NSAIDs, including diclofenac, are asso-
ciated with serious dose-related gastrointestinal, cardiovascular, and
renal adverse events. As a result, the US Food and Drug Administration
and international health authorities have encouraged the use of
NSAIDs at the lowest effective dose for the shortest possible duration.
Diclofenac submicron particle containing capsules (DSPCC) consisting
of submicron drug particles and a proprietary combination of exci-
pients were developed using SoluMatrix Fine Particle Technology to
provide efﬁcacy at lower doses than commercially available diclofenac
drug products and are licensed for treatment of mild-to-moderate
acute pain in adults. In a randomized controlled phase 3 trial (RCT) in
patients with pain due to OA of the knee or hip, DSPCC 35 mg three
times daily (TID) signiﬁcantly reducedWestern Ontario and McMaster
University Osteoarthritis Index (WOMAC) pain subscale scores (P ¼
0.0024) compared with placebo, with non-statistical beneﬁt for the
BID dose (P ¼ 0.0795). We present results of patient-reported out-
comes from this study.
Methods: This 12-week RCT enrolled 305 patients 41 to 90 years of age
with clinically and radiologically conﬁrmed (Kellgren-Lawrence grade
II-III) OA of hip or knee. Patients were chronic NSAID or acetaminophen
users with WOMAC pain subscale scores 40 mm by 100-mm Visual
Analog Scale at baseline and a documented OA ﬂare (15-mm increase)
following NSAID or acetaminophen discontinuation. Eligible patientsg TID (n [ 98) DSPCC 35 mg BID (n [ 104) Placebo (n [ 103)
(n [ 100) (n [ 100)
7.02* 3.87
(n[ 100) (n[ 100)
5.74* 2.83
6.60 4.39
9.25* 5.61
0.92 1.29
4.49* 1.94
4.44 3.07
2.68 3.60
2.18 1.75
ice daily; SF-36, Medical Outcomes Survey Short Form 36 (SF-36), version 2.
5 for physical component score; 5.0 for SF-36 domain scores).
alculated from least-squared mean changes from baseline.
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Global Impression of Change (PGIC) and health related quality-of-life
(HRQOL) by Medical Outcomes Survey Short Form 36 (SF-36), version 2
were assessed.
Results:Mean (SD) agewas 61.6 (8.9) years; two-thirds of patients were
female. Signiﬁcantly more patients receiving DSPCC 35 mg TID (P <
0.0006) and BID (P ¼ 0.0071) reported PGIC as very much or much
improved relative to those reporting very much worse or much worse
compared with placebo. DSPCC 35 mg TID (P ¼ 0.0014) and BID (P ¼
0.0048) recipients also reported statistically greater improvement in
the SF-36 physical component summary score compared with placebo
that exceeded minimally clinically important difference (MCID 2.5;
Table). Those receiving DSPCC 35 mg TID reported signiﬁcant
improvements in 5 SF-36 domains (physical functioning, role physical,
bodily pain, vitality, and social functioning) of which 4 (physical func-
tioning, role physical, bodily pain, and social functioning) were MCID
(5.0; Table). Treatment with DSPCC 35 mg BID resulted in signiﬁcant
(physical functioning, bodily pain, and vitality) and clinically mean-
ingful (physical functioning, bodily pain, and role physical) improve-
ments (Table). Overall, serious AEs were uncommon (DSPCC 35 mg TID
[4/98, 4.1%], BID [3/104, 2.9%], and placebo [2/103, 1.9%]) and included
aspartate aminotransferase and alanine aminotransferase elevations in
a single patient. There were no reports of gastrointestinal ulcer,
bleeding, and perforation or myocardial infarction and stroke.
Conclusions: Investigational, lower-dose DSPCC 35 mg TID and BID
resulted in more patient-reported improvement in PGIC and HRQOL at
12 weeks in patients with OA pain of the hip or knee compared with
placebo. Lower-dose DSPCC was generally well tolerated and offers a
potentially promising therapeutic option for treatment of OA pain.
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SERUM URIC ACID AS A PREDISPOSING FACTOR OF CLINICO-
RADIOLOGICAL SEVERITY OF OSTEOARTHRITIS KNEE
R.N. Srivastava y, D. Sanghi y, A. Mishra y, A.C. Sharma y, S. Raj z,
S.M. Natu y. yKG Med. Univ., Lucknow, India; zMS Ramaiah, Med. Coll.,
Bangalore, India
Purpose: Osteoarthritis (OA) is the most common arthritis worldwide.
The association with age, obesity, gender and metabolic factors has
been studied widely. Evidence suggests that hyperuricemia is sig-
niﬁcantly associated with OA of multiple joints. The high level of uric
acid involved in cartilage degeneration may modulate radiological
features of knee OA. Some study reported that uric acid is associated
with generalized OA and other reported that it is a danger signal of
increasing risk for OA through inﬂammasome activation and concluded
that synovial uric acid is a marker of knee OA severity. Both OA and
hyperuricemia are common in India. This study aimed to investigate the
association of serum uric acid with clinico-radiological feature of knee
OA in Indian population.
Methods: 180 patients of OA knee diagnosed according to American
College of Rheumatology (ACR) guidelines as cases and equal number of
controls were enrolled. Clinical OA outcome: pain, stiffness and func-
tional disability were recorded by kneespeciﬁc WOMAC index and knee
painwas also measured by 10 point VAS. Radiological grading was done
by KL grades. In addition, four individual radiological features (IRF)-
joint space width, osteophyte, subchondral sclerosis and tibio femoral
alignment were also recorded separately. Demographic were recorded
by self report. Serum uric acid levels were measured by enzymatic
method using Uricase - Peroxidase and analyzed for the interlinking
associations.
Results: OA knee cases had signiﬁcant higher BMI than controls in
overall and in both the genders separately. In females, serum uric acid
levels were signiﬁcantly higher in cases in comparison to controls but
such association was not observed in males and in overall subjects.
Other biochemical variable like random blood sugar and total proteins
were not signiﬁcantly different between cases and controls in any cat-
egory. On analyzing serum uric acid level with clinical features, pain
(VAS and WOMAC) was signiﬁcantly associated (p¼0.02 and p¼0.03)
with elevated serum uric acid levels in females; VAS pain alone in
overall study population (p¼0.024) but not inmales.While studying the
radiological features, an increase severity of disease (increasing KL
grades) was observed with increase in serum uric acid levels (KL grade 4
was 5.26  1.1, KL grade 3 was 4.32  0 .95 and KL grade 2 was 3.63 
0.95) in overall subjects and in both the genders separately. Nosigniﬁcant association was observed for individual radiological features
(IRF).
Conclusions: Radiological severity (KL grade) and knee pain was found
to be signiﬁcantly associated with serum uric acid levels in overall
subjects and in females in OA knee.
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CARDIOVASCULAR DISEASES, BIOMECHANICAL FACTORS AND
ACTIVITY LIMITATIONS IN PATIENTS WITH KNEE AND/OR HIP
OSTEOARTHRITIS: RESULTS OF THE AMS-OA STUDY
I.A. van den Oever, M. van der Esch, I. Visman, M. van der Leeden,
M. de Rooij, W. Lems, L. Roorda, M. Nurmohamed, J. Dekker. Jan van
Breemen Res. Inst. Reade, Amsterdam, Netherlands
Purpose: The aim of the study was to investigate differences in bio-
mechanical factors and activity limitations between knee and/or hip
osteoarthritis (OA) patients with and without cardiovascular disease
(CVD).
Methods: A total of 458 consecutive patients from the Amsterdam
Osteoarthritis (AMS-OA) cohort were included in this cross-sectional
study. All patients were diagnosed with OA of the knee and/or hip
according to the ACR criteria and referred to the outpatient rehabil-
itation centre (Reade, Centre for Rehabilitation and Rheumatology,
Amsterdam, the Netherlands). All provided written informed consent.
The Cumulative Illness Rating Scale (CIRS) and a speciﬁc CVD ques-
tionnaire were used to quantify CVD. Coronary diseases including heart
failure and cerebral or peripheral artery diseases were considered as
CVD. Medical ﬁles were checked for validity of the reported CVD. Bio-
mechanical factors were muscle strength, joint proprioception and joint
laxity.Muscle strength was tested with an isokinetic dynamometer,
proprioception with a joint motion detection device and varus-valgus
laxity was assessed as the movement in the frontal plane in a sitting
position. Activity limitations were assessed by Western Ontario and
McMaster University Osteoarthritis Index physical function subscale
(WOMAC-pf) questionnaire and by the get up and go (GUG) and stair-
climb test. Blood samples were taken and markers for inﬂammation,
liver function and kidney function were measured.Analyses were per-
formed with SPSS version 21.0. Unpaired t-tests, Mann-Whitney U tests
or the Pearson Chi-square tests were used to determine signiﬁcant
differences between OA patients with and without CVD.
Results: In total 53 OA patients (11.6%) reported CVD. Sixteen patients
(3.5 %) had coronary diseases, 18 (3.7%) heart failure, 22 (4.6%) cerebral
artery diseases and 3 (0.7%) reported peripheral artery diseases. The
patient characteristics of the total OA population and differences in
biomechanical factors, activity limitations and blood tests between
patients with and without CVD are displayed in table 1.OA patients with
a history of CVDwere signiﬁcantly older andmore oftenmale. They also
had a signiﬁcantly higher BMI compared to OA patients without CVD.
OA patients with CVD had less severe OA according to the Kellgren/
Lawrence score. Knee and/or hip OA patients with CVD showed lower
outcomes for muscle strength, higher scores for proprioception and
laxity and also higher scores for the activity limitations tests. However,
only the scores on the GUG and stair-climb test were signiﬁcantly
higher in patients with CVD.
Flexion and extension muscle strength scores of men with CVD were
signiﬁcantly lower compared to men without CVD (see table 2). In
woman with CVD, these scores were also lower, but only signiﬁcant for
the ﬂexion score. The GUG and stairclimb scores were signiﬁcantly
higher in womenwith CVD compared to womanwithout CVD. For men
this was only true for the stairclimb test up.
The inﬂammatorymarkers, ESR and CRP were not signiﬁcantly different
between patients with and without CVD. The leucocyte count and the
markers ASAT, alkaline phosphatase and creatinin were signiﬁcantly
higher in patients with CVD. These signiﬁcances disappeared when
stratiﬁed for gender, except for AF in women.
Conclusions: Activity limitations and biomechanical factors differ
between knee and/or hip osteoarthritis patients with and without
cardiovascular diseases, whereby patients with CVD seem to have
worse outcomes, compared to patients without CVD. Furthermore,
there are apparent differences between men and woman. Whereas
woman with CVD have signiﬁcantly more activity limitations, the men
with CVD have signiﬁcantly less muscle strength. Future research
should focus on the inﬂuence of cardiovascular disease and its risk
factors on the association between muscle strength and activity limi-
tations.
